ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice"

  • Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting

    The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry

    Philip J Mease1, Carol J. Etzel2, Jeffrey Lisse3, April W Armstrong4, William J Huster3, Sabrina Rebello2, Rhiannon Dodge2, Talia M Muram3, Sarah Al Sawah3, Mwangi J Murage3, Jeffrey D Greenberg2 and William Malatestinic3, 1Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3Eli Lilly and Company, Indianapolis, IN, 4Keck School of Medicine, University of Southern California, Los Angeles, CA

    Background/Purpose:   Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3.  The objective of the…
  • Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting

    Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization

    Douglas C.A. Taylor1, An-Chen Fu1 and Robert Morlock2, 1Ironwood Pharmaceuticals, Inc., Cambridge, MA, 2YourCareChoice, Ann Arbor, MI

    Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
  • Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting

    Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity

    Philip J Mease1, Carol J. Etzel2, Jeffrey Lisse3, April W Armstrong4, William J Huster3, Sabrina Rebello2, Rhiannon Dodge2, Talia M Muram3, Sarah Al Sawah3, Mwangi J Murage3, Jeffrey D Greenberg2 and William Malatestinic3, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3Eli Lilly and Company, Indianapolis, IN, 4Keck School of Medicine, University of Southern California, Los Angeles, CA

    Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
  • Abstract Number: 1233 • 2017 ACR/ARHP Annual Meeting

    Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience

    Narender Annapureddy1, Michelle J. Ormseth2, Julie Barnes3 and James Gore4, 1Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 2Rheumatology, Vanderbilt Medical Center, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Vanderbilt Rheumatology Cool Springs, Franklin, TN

    Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience Background/Purpose: In 2015, about 16% of adults under age 65 in Tennessee were uninsured.…
  • Abstract Number: 1382 • 2017 ACR/ARHP Annual Meeting

    Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus

    Jessica Williams1, Andrew Joyce2, Glenn Gaviola1, Zacharia Isaac1,2 and Joerg Ermann3, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, 3Harvard Medical School, Boston, MA

    Background/Purpose: Formation of pannus, an inflammatory tissue mass, in the atlanto-axial joint of the cervical spine is an important sequela of rheumatoid arthritis (RA). Atlanto-axial…
  • Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting

    Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis

    Zulema Rosales Rosado1,2, Dalifer Freites Núñez2, Cristina Lajas Petisco1, Esperanza Pato Cour1, Leticia Leon2, Judit Font Urgelles1, Juan A Jover Jover1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
  • Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting

    Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice

    Takaaki Komiya1, Kaoru Minegishi-Takase2, Natsuki Sakurai1, Yuichiro Sato1, Hideto Nagai3, Naoki Hamada3, Yumiko Sugiyama3, Naomi Tsuchida1, Yutaro Soejima3, Yosuke Kunishita3, Hiroto Nakano3, Daiga Kishimoto3, Koji Kobayashi2, Reikou Kamiyama3, Ryusuke Yoshimi3, Yukiko Asami3, Yohei Kirino3, Shigeru Ohno4 and Hideaki Nakajima3, 1Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

    Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
  • Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting

    Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study

    Rieke Alten1, HM Lorenz2, X Mariette3, HG Nüßlein4, M Galeazzi5, F Navarro6, M Chartier7, Y Elbez8, C Rauch9 and M Le Bars7, 1Schlosspark-Klinik University Medicine, Berlin, Germany, 2University Hospital, Heidelberg, Germany, 3Université Paris-Sud, Paris, France, 4University of Erlangen, Nürnberg, Germany, 5University of Siena, Siena, Italy, 6Hospital Universitario Virgen Macarena, Seville, Spain, 7Bristol-Myers Squibb, Rueil-Malmaison, France, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Munich, Germany

    Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
  • Abstract Number: 95 • 2017 ACR/ARHP Annual Meeting

    Globalisation of Paediatric Musculoskeletal Matters’ (PMM)

    Nicola Smith1, Sharmila Jandial2, Ruth Wyllie2, Christine English3, Barbara Davies3, Raju Khubchandani4, Mercedes Chan5, Jane Munro6, Virgínia Ferriani7, Claudia Saad Magalhães8, Ricardo Russo9, Jacqueline Yan10, Chris Scott11, Sirirat Charuvanij12, Khulood Khawaja13, Jelena Vojinovic14, Tim Rapley15 and Helen Foster16, 1Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, 2Paediatric Rheumatology, Great North Children’s Hospital, Newcastle Upon Tyne, United Kingdom, 3Department of Nursing, Midwifery and Health, Northumbria University, Newcastle Upon Tyne, United Kingdom, 4Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, 5Paediatric Rheumatology, University of Alberta, Edmonton, AB, Canada, 6Paediatric Rheumatology, Royal Children's Hospital, Victoria, Australia, 7Department of Paediatrics, Ribeirão Preto Medical School, University of São Paulo (USP-RP), Sao Paulo, Brazil, 8Department of Pediatrics, São Paulo State University (UNESP), Botucatu, Brazil, 9Service of Immunology/Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, 10Paediatric Rheumatology, Starship Children’s Health, Auckland, New Zealand, 11Department of Paediatrics, University of Cape Town, Cape Town, South Africa, 12Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand, 13Department of Immunology/Rheumatology, Al-Mafraq Hospital, Abu Dhabi, United Arab Emirates, 14Paediatric Rheumatology, Faculty of Medicine, University of Nis, Nis, Serbia, 15Institute of Health and Society, Newcastle University, Newcastle Upon Tyne, United Kingdom, 16Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

    Background/Purpose: paediatric musculoskeletal matters’ (PMM–www.pmmonline.org) is a free, evidence-based and peer reviewed open e-resource for paediatric musculoskeletal (MSK) medicine targeting non-MSK specialists. Since launch (Nov-2014)…
  • Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting

    Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis

    Uta Kiltz, Thomas Wiatr, Xenofon Baraliakos, Kirill Fedorov and Jürgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…
  • Abstract Number: 186 • 2017 ACR/ARHP Annual Meeting

    Paediatric Musculoskeletal (MSK) Triage in the Community – Rightpath – a Pilot Study

    Nicola Smith1, Sharmila Jandial2, Jill Firth3, Helen Light3, Katharine Kinsey3, Neil Snowden3, Judith McNaught4, Tim Rapley5, Alan Nye3 and Helen E. Foster6, 1Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, 2Paediatric Rheumatology, Great North Children’s Hospital, Newcastle Upon Tyne, United Kingdom, 3Pennine MSK Partnership Ltd, Oldham, United Kingdom, 4Physiotherapy, South Tyneside NHS Foundation Trust, South Shields, United Kingdom, 5Institute of Health and Society, Newcastle University, Newcastle Upon Tyne, United Kingdom, 6Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

    Background/Purpose: We are piloting a children and young people (CYP) community-based triage (called Rightpath) based on a validated adult MSK triage model developed by Pennine…
  • Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting

    Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data

    Rosa Expósito1, Carlos M Gonzalez2, Rosa García-Portales3, Ana Urruticoechea-Arana4, Jose Ramon Lamua5, Maria del Pilar Navarro6, José Santos Rey Rey7 and Manuel Fernández8, 1Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 2Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, 3Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, 4Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 5Hospital del Henares, Madrid, Spain, 6Hospital de Fuenlabrada, Fuenlabrada, Spain, 7Hospital Virgen de la Salud, Toledo, Spain, 8H. Guadalajara, Guadalajara, Spain

    Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
  • Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting

    Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate

    Michael D. George1, Brian Sauer2, Chia-Chen Teng, MS2, Grant Cannon2, Bryant R. England3, Gail S. Kerr4, Ted R. Mikuls5 and Joshua Baker6, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4VAMC, Georgetown University, Washington, DC, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
  • Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting

    Opioid Use in Patients with Ankylosing Spondylitis

    Victor S. Sloan1, Anna Sheahan1, Jeffrey Stark2 and Robert Y. Suruki1, 1UCB Pharma, Raleigh, NC, 2UCB Pharma, Smyrna, GA

    Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…
  • Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting

    Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis

    Lydia A Alcazar1, Judit Font Urgelles2, Cynthia Milagros León Cárdenas2, Cristina Vadillo Font2, Dalifer Freites Núñez1, Leticia Leon1, Juan A Jover Jover2 and Zulema Rosales Rosado1,2, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology